We have collected information about Elp Drug Delivery Osteoarthritus for you. Follow the links to find out details on Elp Drug Delivery Osteoarthritus.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167344/
Sep 28, 2014 · A unimer ELP carrier can provide advantages in drug delivery by improving the pharmacokinetics and biodistribution of its drug cargo, as compared to the behavior of free drug alone.Author: Sarah R. MacEwan, Ashutosh Chilkoti
https://www.sciencedirect.com/science/article/pii/S1359644618300461
Schematic representation of the retention time and clearance of various biodegradable osteoarthritis (OA) drug delivery systems (DDSs) after intra-articular (IA) administration. Free drugs, hydrogel, nanoparticles and microparticles remain in the joint for hours, days, weeks and months, respectively.Author: Pierre Maudens, Olivier Jordan, Eric Allémann
https://www.ncbi.nlm.nih.gov/pubmed/29792929
To satisfy this unmet medical need, drug delivery systems (DDSs) containing disease-modifying OA drugs (DMOADs) for intra-articular (IA) administration are required to improve the health of OA patients. DDSs should provide controlled and/or sustained drug release, enabling long-term treatment with a reduced number of injections.Author: Pierre Maudens, Olivier Jordan, Eric Allémann
https://www.sciencedirect.com/science/article/pii/S0168365906003695
The ELP drug delivery vehicle was designed to aggregate upon intra-articular injection at 37 °C, and form a drug ‘depot’ that could slowly disaggregate and be cleared from the joint space over time.Author: Helawe Betre, Wenge Liu, Michael R. Zalutsky, Ashutosh Chilkoti, Virginia B. Kraus, Lori A. Setton
https://www.aiche.org/resources/publications/cep/2018/may/designing-drug-delivery-systems-articular-joints
No disease-modifying drug exists for osteoarthritis due to poor drug delivery within joints. Engineered biomaterials could address this challenge by improving the duration and targeting of therapies. Osteoarthritis is a debilitating disease of individual joints, marked by progressive joint tissue degeneration, which causes pain and loss of mobility.
https://chilkotilab.pratt.duke.edu/content/injectable-elp-depots-drug-delivery
Injectable ELP Depots for Drug Delivery We have several projects in the area of injectable drug delivery depots: (1) in a project on the intratumoral delivery of radionuclides, we have covalently conjugated radionuclides to an ELP with a transition temperature below body temperature and injected these conjugates directly into tumors.
http://europepmc.org/articles/PMC2817653
Feb 01, 2010 · Local drug delivery strategies may provide for the development of more successful OA treatment outcomes that have potential to reduce local joint inflammation, reduce joint destruction, offer pain relief, and restore patient activity levels and joint function.
https://www.nature.com/articles/nrrheum.2016.210
Current intra-articular drug delivery methods do not guarantee sufficient drug penetration into cartilage tissue to reach cell and matrix targets at the concentrations necessary to elicit the desired biological response.Author: Ambika G. Bajpayee, Alan J. Grodzinsky
https://www.researchgate.net/publication/6831684_A_thermally_responsive_biopolymer_for_intra-articular_drug_delivery
The ELP drug delivery vehicle was designed to aggregate upon intra-articular injection at 37 degrees C, and form a drug 'depot' that could slowly disaggregate and be cleared from the joint space ...
Searching for Elp Drug Delivery Osteoarthritus?
You can just click the links above. The data is collected for you.
